Annual report [Section 13 and 15(d), not S-K Item 405]

STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY

v3.25.4
STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total
Balance at beginning at Dec. 31, 2023 $ 723 $ 57,884,815 $ (53,218,853) $ 4,666,685
Balance at beginning (in shares) at Dec. 31, 2023 723,411      
Share-Based Compensation   2,601,903   2,601,903
Share-Based Payments to Vendors $ 18 833,662   833,680
Share-Based Payments to Vendors (in shares) 17,659      
Issuance of shares of common stock in At-the-Market sales agreement, net of $209,305 cash issuance costs $ 108 6,405,649   6,405,757
Issuance of shares of common stock in At-the-Market sales agreement, net of $209,305 cash issuance costs (in shares) 107,504      
Warrant Exercise $ 3 210,196   210,199
Warrant Exercise (in shares) 2,960      
Net Loss     (14,103,103) (14,103,103)
Balance at ending at Dec. 31, 2024 $ 852 67,936,225 (67,321,956) $ 615,121
Balance at ending (in shares) at Dec. 31, 2024 851,534     851,534
Reverse Stock Split fractional share adjustment   (1,040)   $ (1,040)
Reverse Stock Split fractional share adjustment (in shares) (167)      
Share-Based Compensation   1,247,401   1,247,401
Share-Based Compensation to settle accrued compensation   413,120   413,120
Share-Based Payments to Vendors $ 48 322,271   322,319
Share-Based Payments to Vendors (in shares) 47,643      
Issuance of shares of common stock in January Registered Direct Offering, net of $400,750 cash issuance costs $ 123 2,099,130   2,099,253
Issuance of shares of common stock in January Registered Direct Offering, net of $400,750 cash issuance costs (in shares) 123,153      
Issuance of shares of common stock and pre-funded warrants in March Registered Direct Offering, net of $208,580 cash issuance costs $ 107 889,313   889,420
Issuance of shares of common stock and pre-funded warrants in March Registered Direct Offering, net of $208,580 cash issuance costs (in shares) 107,500      
Pre-funded Warrant Exercise $ 30 (30)    
Pre-funded Warrant Exercise (in shares) 29,750      
Issuance of shares of common stock related to equity line of credit purchase agreement, net of $144,991 cash issuance costs $ 796 3,807,643   3,808,439
Issuance of shares of common stock related to equity line of credit purchase agreement, net of $144,991 cash issuance costs (in shares) 796,360      
Issuance of shares of common stock related to warrant inducement, net of $186,708 cash issuance costs $ 222 2,480,331   2,480,553
Issuance of shares of common stock related to warrant inducement, net of $186,708 cash issuance costs (in shares) 222,272      
Warrant Exercise $ 170 1,360,374   $ 1,360,544
Warrant Exercise (in shares) 170,068     422,090
Net Loss     (7,966,538) $ (7,966,538)
Balance at ending at Dec. 31, 2025 $ 2,348 $ 80,554,738 $ (75,288,494) $ 5,268,592
Balance at ending (in shares) at Dec. 31, 2025 2,348,113     2,348,113